IntHyx : Intubation Strategies for Patients With Acute Hypoxemic Respiratory Failure
NCT ID: NCT07189078
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
200 participants
INTERVENTIONAL
2025-12-13
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An ideal intubation strategy would therefore strike a balance: avoiding the risks of delayed intubation-such as refractory hypoxemia, excessive respiratory effort, and patient self-inflicted lung injury (P-SILI)-while limiting complications associated with invasive mechanical ventilation by withholding it in patients who might otherwise recover without. To date, the optimal strategy for achieving this risk-benefit balance remains uncertain.
Clinical practice suggests a broad consensus on the necessity of intubation when so-called safety criteria are met: severe hypoxemia (SaO₂/FiO₂ ratio \< 88), marked respiratory distress (use of accessory muscles, thoracoabdominal paradox, respiratory rate \> 40/min), extra-respiratory manifestations of hypoxia (e.g., altered consciousness), and/or uncontrolled hemodynamic instability. Beyond these safety thresholds, however, debate persists. Some advocate for earlier intubation-a so-called liberal approach-triggered by predefined hypoxemia criteria (e.g., SpO₂/FiO₂ \< 110), with the aim of limiting the deleterious consequences of sustained hypoxemia.
In routine practice, the criteria guiding intubation vary widely between clinicians and cannot be attributed to strong scientific evidence. This study therefore seeks to compare, in a randomized interventional design, the two main strategies currently applied across centers:
* Liberal intubation strategy: prioritizing the prevention of organ dysfunction related to hypoxemia (notably hypoxic cardiac arrest) and the risk of P-SILI.
* Restrictive intubation strategy: prioritizing the reduction of invasive mechanical ventilation use, with the goal of minimizing ventilation-related harm and its associated therapeutic burden.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
"Liberal" intubation strategy
Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.
In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes.
Liberal intubation strategy
Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.
In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes.
Restrictive intubation strategy
Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:
1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.
2. SpO₂/FiO₂ \< 88.
3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels.
Restrictive intubation strategy
Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:
1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.
2. SpO₂/FiO₂ \< 88.
3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Restrictive intubation strategy
Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:
1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.
2. SpO₂/FiO₂ \< 88.
3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels.
Liberal intubation strategy
Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.
In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient admitted to intensive care less than 24 hours ago
* Acute respiratory failure with hypoxemia defined by either:
* Oxygen therapy ≥ 10 L/min via high-concentration mask required for SpO2 ≥ 92%
* High-flow oxygen therapy with FiO2 ≥ 50% required for SpO2 ≥ 92%
* Informed consent of the patient or a trusted relative (when the patient is unable to give consent)
Exclusion Criteria
* Cardiogenic pulmonary edema
* Exacerbation of chronic respiratory disease
* Respiratory failure requiring long-term oxygen therapy
* Neuromuscular disease
* Glasgow Coma Scale score ≤ 12
* Decision to intubate immediately
* Invasive mechanical ventilation within the previous 7 days
* Treatment limitation decisions for intubation
* Person deprived of liberty by judicial or administrative decision : Person undergoing compulsory psychiatric care, person subject to legal protection measures, Pregnant, breastfeeding, or parturient patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Angers
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mathilde TAILLANTOU-CANDAU, Doctor
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Angers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Angers University Hospital, ICU
Angers, , France
Le Mans Hospital, ICU
Le Mans, , France
Nantes University Hospital, ICU
Nantes, , France
Orléans University hospital, ICU
Orléans, , France
Pitié-Salpétrière Hospital, Paris University Hospital, ICU
Paris, , France
Guadeloupe University Hospital, ICU
Pointe à Pitre, , France
Rennes University Hospital, ICU
Rennes, , France
Tours University Hospital, ICU
Tours, , France
Vannes Hospital, ICU
Vannes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Mathilde TAILLANTOU-CANDAU, Doctor
Role: CONTACT
Phone: +33 (0)2 41 35 58 65
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mathilde TAILLANTOU-CANDAU, Doctor
Role: primary
Christophe GUITTON, Professor
Role: primary
Jean REIGNIER, Professor
Role: primary
Mai-Anh NAY, Doctor
Role: primary
Martin DRES, Professor
Role: primary
Frédéric MARTINO, Doctor
Role: primary
Arnaud GACOUIN, Doctor
Role: primary
Pierre-François DEQUIN, Professor
Role: primary
Agathe DELBOVE, Doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-A01380-49
Identifier Type: OTHER
Identifier Source: secondary_id
49RC24_0293
Identifier Type: -
Identifier Source: org_study_id